


Amendments to the Specification

Please replace the paragraph at page 2, line 18 – 20 with the following amended paragraph:

R⁵ is selected from an optionally substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**, **III-g** , **III-h**, **III-i** or **III-j** or **III-k**:

Please replace the paragraph at page 3, lines 6-9 with the following amended paragraph:


R⁷ represents hydrogen or optionally substituted C₁₋₈alkyl;

or  together from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S,

and **R^{6a}** represents hydrogen ~~and~~ or optionally substituted C₁₋₈alkyl;

Please replace the paragraph at page 7, lines 22- page 8, line 2 with the following amended paragraph:


Preferably **R²** represents an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, **NR³[^e]****R^{3a}[^f]**, optionally substituted C₁₋₈alkyl (preferably, C₁₋₄alkyl, eg, methyl or ethyl), optionally substituted C₁₋₈alkoxy (preferably, C₁₋₆alkoxy, eg, methoxy, ethoxy or *tert*-butoxy) or halo (eg, F, Br or Cl) wherein **R³[^e]** and **R^{3a}[^f]** are independently selected from hydrogen, C₁₋₆alkyl or aryl. Further preferably **R²** is optionally substituted phenyl wherein the optional substituents are selected from cyano, **NR³[^e]****R^{3a}[^f]**, optionally substituted C₁₋₄alkyl, optionally substituted C₁₋₆alkoxy, F, Br or Cl wherein **R³[^e]** and **R^{3a}[^f]** are as defined above. Yet further preferably **R²** is optionally substituted phenyl wherein the optional substituents are selected from methyl, ethyl, methoxy, ethoxy, *tert*-butoxy, F or Cl. Most preferably **R²** represents



wherein Me represents methyl. Preferably **R²** bears 1, 2 or 3 substituents.

Please replace the paragraph at page 8, lines 6-8 with the following amended paragraph:

Preferably R^5 is selected from a group of formula **III-a**, **III-g**, **III-h**, or **III-i** or **III-j**:



Please replace the paragraph at page 9, line 21 – page 10, line 4 with the following amended paragraph:

Preferably R^9 comprise part of the group $N(R^9R^{10})$ or is hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C₁₋₄alkyl wherein the optional substituents are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$ [[.]] and $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined above.

Please replace the paragraph at page 10, line 19 – page 11, line 3 with the following amended paragraph:

R^{16} represents hydrogen, aryl, a 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl wherein the optional substituents are selected from: hydroxy, amino, nitro, cyano, optionally-substituted phenyl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$ and $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined above;

Please replace the paragraph at page 11, line 20 – page 12 line 5 with the following amended paragraph:

Most preferably the structure $N(R^9R^{10})$ is a group of formula **V-c**:
 R^{15} represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-4} alkyl are selected from: hydroxy, amino, nitro, cyano, halo, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$ and $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined above. Preferably R^{15} is heterocyclyl. Further preferably R^{15} is selected from: pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl or thiazolyl. Most preferably R^{15} is pyridyl.

Please replace the paragraph at page 16, lines 13-17 with the following amended paragraph:

A preferred compound according to the present invention is:

3-[2,2-dimethyl-3-oxo-3-(Z-azabicyclo[2.2.1]heptan-7-yl)propoxy]-4-[(1S)-1-methyl-2-[(N'-isopropoxycarbonyl)imino(-3-pyridin-4-yl-pyrrolidin-1-yl)methyl]carboximidamide)aminoethyl]-5-(3,5-dimethylphenyl)-1H-pyrazole;
or a salt, pro-drug or solvate thereof.

In case further clarification is needed, the paragraph at page 16, lines 13-17 should now read:

A preferred compound according to the present invention is:

3-[2,2-dimethyl-3-oxo-3-(7-azabicyclo[2.2.1]heptan-7-yl)propoxy]-4-[(1S)-1-methyl-2-[(isopropoxycarbonyl)imino(3-pyridin-4-yl-pyrrolidin-1-yl)methyl]aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole;
or a salt, pro-drug or solvate thereof.

Please replace the paragraph at page 28, lines 5-6 with the following amended paragraph:

3-[2,2-dimethyl-3-oxo-3-(pyrrolidin-1-yl)propoxy]-4-[2-(3-pyridin-4-ylpyrrolidin-1-ylcarboxamido)ethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

In case further the paragraph at is needed, paragraph page 28, lines 5-6 should now read:

3-[2,2-dimethyl-3-oxo-3-(pyrrolidin-1-yl)propoxy]-4-[2-(3-pyridin-4-ylpyrrolidin-1-ylcarboxamido)ethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

Please replace the paragraph at page 29, lines 2-4 with the following amended paragraph:

3-[2,2-dimethyl-3-oxo-3-pyrrolidin-1-ylpropoxy(azabicyclo[2.2.1]heptan-7-yl)propyl]-4-[2-[(N¹-isopropoxycarbonyl)imino-(3-pyridin-4-yl-pyrrolidin-1-ylcarboximidamido)methyl]aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

In case further clarification is needed, the paragraph at page 29, lines 2-4 should now read:

3-[2,2-dimethyl-3-oxo-3-pyrrolidin-1-ylpropoxy]-4-[2-[(isopropoxycarbonyl)imino(3-pyridin-4-yl-pyrrolidin-1-yl)methyl]aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

Please replace the paragraph at page 30, lines 18-20 with the following amended paragraph:

3-[2,2-dimethyl-3-oxo-3-(N,N-diethylamino)propoxyyl]-4-[2-[(N¹-isopropoxycarbonyl)imino(-3-pyridin-4-yl-pyrrolidin-1-yl)methyl]carboximidamido)aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

In case further clarification is needed, the paragraph at page 30, lines 18-20 should now read:

3-[2,2-dimethyl-3-oxo-3-(N,N-diethylamino)propoxy]-4-[2-[(isopropoxycarbonyl)imino(3-pyridin-4-yl-pyrrolidin-1-yl)methyl]aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

Please replace the paragraph at page 33, lines 15-16 with the following amended paragraph:

3-[2,2-dimethyl-3-oxo-3-(N,N-diethylamino)propoxy]-4-[2-(3-pyridin-4-ylpyrrolidin-1-ylcarboxamido)ethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

In case further clarification is needed, the paragraph at page 33, lines 15-16 should now read:

3-[2,2-dimethyl-3-oxo-3-(N,N-diethylamino)propoxy]-4-[2-(3-pyridin-4-ylpyrrolidin-1-ylcarboxamido)ethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

Please replace the paragraph at page 34, lines 4-6 with the following amended paragraph:

3-[2,2-dimethyl-3-oxo-3-(7-azabicyclo[2.2.1]heptan-7-yl)propoxy]-4-[(1*S*)-1-methyl-2-[(N'-isopropoxycarbonyl)imino(3-pyridin-4-yl-pyrrolidin-1-yl)methyl]carboximidamido)aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

In case further clarification is needed, the paragraph at page 34, lines 4-6 should now read:

3-[2,2-dimethyl-3-oxo-3-(7-azabicyclo[2.2.1]heptan-7-yl)propoxy]-4-[(1*S*)-1-methyl-2-[(isopropoxycarbonyl)imino(3-pyridin-4-yl-pyrrolidin-1-yl)methyl]aminoethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

Please replace the paragraph at page 37, lines 2-3 with the following amended paragraph:

3-[2,2-dimethyl-3-oxo-3-(7-azabicyclo[2.2.1]heptan-7-yl)propoxy]-4-[(1*S*)-1-methyl-2-(3-pyridin-4-ylpyrrolidin-1-ylcarboxamido)ethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole

Application No.
Amendment Dated

10/525,111
01/23/2007

In case further clarification is needed, the paragraph at page 37, lines 2-3 should now read:

3-[2,2-dimethyl-3-oxo-3-(7-azabicyclo[2.2.1]heptan-7-yl)propoxy]-4-[(1S)-1-methyl-2-(3-pyridin-4-ylpyrrolidin-1-ylcarboxamido)ethyl]-5-(3,5-dimethylphenyl)-1*H*-pyrazole